NCT02078492View on ClinicalTrials.gov

A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management

PHASE4CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Pain
Interventions
DRUG

10 mg of Ketorolac

Patients will receive 10 mg of Ketorolac for pain control.

DRUG

15 mg of Ketorolac

Patients will receive 15mg of Ketorolac for pain control.

DRUG

30 mg of Ketorolac

Patients will receive 30mg of Ketorolac for pain control.

Trial Locations (1)

11219

Maimonides Medical Center, Brooklyn

All Listed Sponsors
lead

Antonios Likourezos

OTHER

NCT02078492 - A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management | Biotech Hunter | Biotech Hunter